HEADER CHAPERONE 05-JUN-12 4AWP TITLE COMPLEX OF HSP90 ATPASE DOMAIN WITH TROPANE DERIVED INHIBITORS COMPND MOL_ID: 1; COMPND 2 MOLECULE: HEAT SHOCK PROTEIN HSP 90-ALPHA; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: ATPASE DOMAIN, RESIDUES 9-236; COMPND 5 SYNONYM: HEAT SHOCK 86 KDA, HSP 86, HSP86, RENAL CARCINOMA ANTIGEN COMPND 6 NY-REN-38, HSP90; COMPND 7 EC: 3.6.4.10; COMPND 8 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS CHAPERONE, INHIBITOR EXPDTA X-RAY DIFFRACTION AUTHOR J.C.LOUGHEED,T.J.STOUT REVDAT 2 01-MAY-24 4AWP 1 REMARK REVDAT 1 29-AUG-12 4AWP 0 JRNL AUTH J.BUSSENIUS,C.M.BLAZEY,N.AAY,N.K.ANAND,A.ARCALAS,T.BAIK, JRNL AUTH 2 O.J.BOWLES,C.A.BUHR,S.COSTANZO,J.K.CURTIS,S.C.DEFINA, JRNL AUTH 3 L.DUBENKO,T.S.HEUER,P.HUANG,C.JAEGER,A.JOSHI,A.R.KENNEDY, JRNL AUTH 4 A.I.KIM,K.LARA,J.LEE,J.LI,J.C.LOUGHEED,S.MA,S.MALEK, JRNL AUTH 5 J.C.MANALO,J.F.MARTINI,G.MCGRATH,M.NICOLL,J.M.NUSS,M.PACK, JRNL AUTH 6 C.J.PETO,T.H.TSANG,L.WANG,S.W.WOMBLE,M.YAKES,W.ZHANG, JRNL AUTH 7 K.D.RICE JRNL TITL DISCOVERY OF XL888: A NOVEL TROPANE-DERIVED SMALL MOLECULE JRNL TITL 2 INHIBITOR OF HSP90. JRNL REF BIOORG.MED.CHEM.LETT. V. 22 5396 2012 JRNL REFN ISSN 0960-894X JRNL PMID 22877636 JRNL DOI 10.1016/J.BMCL.2012.07.052 REMARK 2 REMARK 2 RESOLUTION. 1.82 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.2.0019 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.82 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 53.99 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 90.3 REMARK 3 NUMBER OF REFLECTIONS : 37837 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.207 REMARK 3 R VALUE (WORKING SET) : 0.205 REMARK 3 FREE R VALUE : 0.246 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 2009 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.82 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.87 REMARK 3 REFLECTION IN BIN (WORKING SET) : 2780 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 90.60 REMARK 3 BIN R VALUE (WORKING SET) : 0.3340 REMARK 3 BIN FREE R VALUE SET COUNT : 164 REMARK 3 BIN FREE R VALUE : 0.4290 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 3224 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 76 REMARK 3 SOLVENT ATOMS : 279 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 24.85 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.01000 REMARK 3 B22 (A**2) : 0.07000 REMARK 3 B33 (A**2) : 0.02000 REMARK 3 B12 (A**2) : -0.01000 REMARK 3 B13 (A**2) : 0.78000 REMARK 3 B23 (A**2) : -0.25000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.153 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.145 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.097 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 3.094 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.948 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.931 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 3358 ; 0.019 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 4532 ; 1.672 ; 1.986 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 404 ; 6.296 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 148 ;37.416 ;25.135 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 612 ;14.779 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 14 ;20.187 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 516 ; 0.211 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 2484 ; 0.008 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 1590 ; 0.208 ; 0.020 REMARK 3 NON-BONDED CONTACTS OTHERS (A): 1590 ; 0.208 ; 0.200 REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 2287 ; 0.300 ; 0.200 REMARK 3 NON-BONDED TORSION OTHERS (A): 2287 ; 0.300 ; 0.200 REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 213 ; 0.151 ; 0.200 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 38 ; 0.189 ; 0.200 REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 6 ; 0.171 ; 0.200 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 2095 ; 1.071 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 3262 ; 1.682 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 1456 ; 2.524 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 1270 ; 3.792 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.40 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. REMARK 4 REMARK 4 4AWP COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 05-JUN-12. REMARK 100 THE DEPOSITION ID IS D_1290052769. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 30-NOV-06 REMARK 200 TEMPERATURE (KELVIN) : 93.2 REMARK 200 PH : 8 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SSRL REMARK 200 BEAMLINE : BL9-2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.97946 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 39846 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.740 REMARK 200 RESOLUTION RANGE LOW (A) : 44.980 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 78.7 REMARK 200 DATA REDUNDANCY : 1.950 REMARK 200 R MERGE (I) : 0.18000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 8.3600 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.74 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.86 REMARK 200 COMPLETENESS FOR SHELL (%) : 27.5 REMARK 200 DATA REDUNDANCY IN SHELL : 1.89 REMARK 200 R MERGE FOR SHELL (I) : 0.75000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 1.140 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: IN-HOUSE APO STRUCTURE REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 51.10 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.54 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PH 8 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1610 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 20550 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -12.1 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 7 REMARK 465 SER A 8 REMARK 465 ASP A 9 REMARK 465 GLN A 10 REMARK 465 PRO A 11 REMARK 465 MET A 12 REMARK 465 GLU A 13 REMARK 465 GLU A 14 REMARK 465 GLU A 15 REMARK 465 GLU A 16 REMARK 465 ALA A 124 REMARK 465 GLY A 125 REMARK 465 ALA A 126 REMARK 465 LYS A 224 REMARK 465 GLU A 225 REMARK 465 ARG A 226 REMARK 465 ASP A 227 REMARK 465 LYS A 228 REMARK 465 GLU A 229 REMARK 465 VAL A 230 REMARK 465 SER A 231 REMARK 465 ASP A 232 REMARK 465 ASP A 233 REMARK 465 GLU A 234 REMARK 465 ALA A 235 REMARK 465 GLU A 236 REMARK 465 GLY B 7 REMARK 465 SER B 8 REMARK 465 ASP B 9 REMARK 465 GLN B 10 REMARK 465 PRO B 11 REMARK 465 MET B 12 REMARK 465 GLU B 13 REMARK 465 GLU B 14 REMARK 465 GLU B 15 REMARK 465 GLU B 16 REMARK 465 ALA B 124 REMARK 465 GLY B 125 REMARK 465 ALA B 126 REMARK 465 LYS B 224 REMARK 465 GLU B 225 REMARK 465 ARG B 226 REMARK 465 ASP B 227 REMARK 465 LYS B 228 REMARK 465 GLU B 229 REMARK 465 VAL B 230 REMARK 465 SER B 231 REMARK 465 ASP B 232 REMARK 465 ASP B 233 REMARK 465 GLU B 234 REMARK 465 ALA B 235 REMARK 465 GLU B 236 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O SER B 39 O HOH B 2011 2.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASN A 40 52.67 -92.55 REMARK 500 ASN A 106 170.01 71.10 REMARK 500 ALA A 166 -143.48 72.29 REMARK 500 ASN B 40 51.56 -92.70 REMARK 500 ASN B 106 170.72 70.41 REMARK 500 GLN B 133 29.97 -78.79 REMARK 500 ALA B 166 -147.56 64.33 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A2087 DISTANCE = 6.04 ANGSTROMS REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 99A B 1224 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 99A A 1224 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1BYQ RELATED DB: PDB REMARK 900 HSP90 N-TERMINAL DOMAIN BOUND TO ADP-MG REMARK 900 RELATED ID: 1OSF RELATED DB: PDB REMARK 900 HUMAN HSP90 IN COMPLEX WITH 17-DESMETHOXY-17-N,N- REMARK 900 DIMETHYLAMINOETHYLAMINO-GELDANAMYCIN REMARK 900 RELATED ID: 1UY6 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3,4,5-TRIMETHOXY -BENZYL)-9H- REMARK 900 PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UY7 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(4-METHOXY-BENZYL )-9H-PURIN-6- REMARK 900 YLAMINE REMARK 900 RELATED ID: 1UY8 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3-TRIMETHOXY- BENZYL)-9H-PURIN- REMARK 900 6YLAMINE REMARK 900 RELATED ID: 1UY9 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-BENZO[1,3]DIOXOL-,5- YLMETHYL-9-BUTYL-9H- REMARK 900 PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYC RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5-DIMETHOXY- BENZYL)-9H-PURIN-6- REMARK 900 YLAMINE REMARK 900 RELATED ID: 1UYD RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2-CHLORO-3,4,5 -TRIMETHOXY-BENZYL) REMARK 900 -9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYE RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4,5- TRIMETHOXY-BENZYL)-9-PENT- REMARK 900 4-YLNYL-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYF RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4,5- TRIMETHOXY-BENZYL)-2- REMARK 900 FLUORO-9-PENT-4-YLNYL-9H-PURIN -6-YLAMINE REMARK 900 RELATED ID: 1UYG RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY-BENZYL)-2- FLUORO-9H-PURIN- REMARK 900 6-YLAMINE REMARK 900 RELATED ID: 1UYH RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5-DIMETHOXY- BENZYL)-2-FLUORO- REMARK 900 9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYI RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY-BENZYL)-2- FLUORO-9-PENT-9H- REMARK 900 PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYK RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-BENZO[1,3]DIOXOL-,5- YLMETHYL-9-BUTYL-2- REMARK 900 FLUORO-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYL RELATED DB: PDB REMARK 900 STRUCTURE-ACTIVITY RELATIONSHIPS IN PURINE-BASED INHIBITOR BINDING REMARK 900 TO HSP90 ISOFORMS REMARK 900 RELATED ID: 1YC1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURES OF HUMAN HSP90ALPHA COMPLEXED REMARK 900 WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 1YC3 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED REMARK 900 WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 1YC4 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED REMARK 900 WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 1YER RELATED DB: PDB REMARK 900 HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "CLOSED" CONFORMATION REMARK 900 RELATED ID: 1YES RELATED DB: PDB REMARK 900 HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "OPEN" CONFORMATION REMARK 900 RELATED ID: 1YET RELATED DB: PDB REMARK 900 GELDANAMYCIN BOUND TO THE HSP90 GELDANAMYCIN-BINDING DOMAIN REMARK 900 RELATED ID: 2BSM RELATED DB: PDB REMARK 900 NOVEL, POTENT SMALL MOLECULE INHIBITORS OF THE MOLECULAR CHAPERONE REMARK 900 HSP90 DISCOVERED THROUGH STRUCTURE-BASED DESIGN REMARK 900 RELATED ID: 2BT0 RELATED DB: PDB REMARK 900 NOVEL, POTENT SMALL MOLECULE INHIBITORS OF THE MOLECULAR CHAPERONE REMARK 900 HSP90 DISCOVERED THROUGH STRUCTURE-BASED DESIGN REMARK 900 RELATED ID: 2BUG RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE TPR DOMAIN FROM PROTEIN PHOSPHATASE 5 IN REMARK 900 COMPLEX WITH HSP90 DERIVED PEPTIDE REMARK 900 RELATED ID: 2BYH RELATED DB: PDB REMARK 900 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE-4- CARBOXAMIDES AS REMARK 900 INHIBITORS OF THE HSP90 MOLECULAR CHAPERONE REMARK 900 RELATED ID: 2BYI RELATED DB: PDB REMARK 900 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE-4- CARBOXAMIDES AS REMARK 900 INHIBITORS OF THE HSP90 MOLECULAR CHAPERONE REMARK 900 RELATED ID: 2BZ5 RELATED DB: PDB REMARK 900 STRUCTURE-BASED DISCOVERY OF A NEW CLASS OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2C2L RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE CHIP U-BOX E3 UBIQUITIN LIGASE REMARK 900 RELATED ID: 2CCS RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H- PYRAZOL-3-YL)- REMARK 900 BENZENE-1,2-DIOL REMARK 900 RELATED ID: 2CCT RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 5-(5-CHLORO-2,4-DIHYDROXY-PHENYL)- 4-PIPERAZIN-1- REMARK 900 YL-2H-PYRAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE REMARK 900 RELATED ID: 2CCU RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 4-CHLORO-6-(4-(4-(4- METHANESULPHONYL-BENZYL)- REMARK 900 PIERAZIN-1-YL)-1H-PYRAZOL-3- YL)-BENZENE-1,3-DIOL REMARK 900 RELATED ID: 2FWY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT WATERSOLUBLE REMARK 900 INHIBITOR PU-H64 REMARK 900 RELATED ID: 2FWZ RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT WATERSOLUBLE REMARK 900 INHIBITOR PU-H71 REMARK 900 RELATED ID: 2JJC RELATED DB: PDB REMARK 900 HSP90 ALPHA ATPASE DOMAIN WITH BOUND SMALL MOLECULE FRAGMENT REMARK 900 RELATED ID: 2UWD RELATED DB: PDB REMARK 900 INHIBITION OF THE HSP90 MOLECULAR CHAPERONE IN VITRO AND IN VIVO BY REMARK 900 NOVEL, SYNTHETIC, POTENT RESORCINYLIC PYRAZOLE, ISOXAZOLE AMIDE REMARK 900 ANALOGS REMARK 900 RELATED ID: 2VCI RELATED DB: PDB REMARK 900 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: POTENTIAL REMARK 900 THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER REMARK 900 RELATED ID: 2VCJ RELATED DB: PDB REMARK 900 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: POTENTIAL REMARK 900 THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER REMARK 900 RELATED ID: 2WI1 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2WI2 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2WI3 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2WI4 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2WI5 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2WI6 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2WI7 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2XAB RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH AN INHIBITOR BOUND REMARK 900 RELATED ID: 2XDK RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XDL RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XDS RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XDU RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XDX RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XHR RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XHT RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XHX RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XJG RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XJJ RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XJX RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XK2 RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2YE2 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YE3 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YE4 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YE5 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YE6 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YE7 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YE8 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YE9 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YEA RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YEB RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YEC RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YED RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YEE RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YEF RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YEG RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YEH RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YEI RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YEJ RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING REMARK 900 RELATED ID: 2YI0 RELATED DB: PDB REMARK 900 STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- 2-4- REMARK 900 DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 INHIBITORS. REMARK 900 RELATED ID: 2YI5 RELATED DB: PDB REMARK 900 STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- 2-4- REMARK 900 DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 INHIBITORS. REMARK 900 RELATED ID: 2YI6 RELATED DB: PDB REMARK 900 STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- 2-4- REMARK 900 DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 INHIBITORS. REMARK 900 RELATED ID: 2YI7 RELATED DB: PDB REMARK 900 STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- 2-4- REMARK 900 DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 INHIBITORS. REMARK 900 RELATED ID: 2YJW RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YJX RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YK2 RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YK9 RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YKB RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YKC RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YKE RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YKI RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YKJ RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 4AIF RELATED DB: PDB REMARK 900 AIP TPR DOMAIN IN COMPLEX WITH HUMAN HSP90 PEPTIDE REMARK 900 RELATED ID: 4AWO RELATED DB: PDB REMARK 900 COMPLEX OF HSP90 ATPASE DOMAIN WITH TROPANE DERIVED INHIBITORS REMARK 900 RELATED ID: 4AWQ RELATED DB: PDB REMARK 900 COMPLEX OF HSP90 ATPASE DOMAIN WITH TROPANE DERIVED INHIBITORS DBREF 4AWP A 9 236 UNP P07900 HS90A_HUMAN 9 236 DBREF 4AWP B 9 236 UNP P07900 HS90A_HUMAN 9 236 SEQADV 4AWP GLY A 7 UNP P07900 EXPRESSION TAG SEQADV 4AWP SER A 8 UNP P07900 EXPRESSION TAG SEQADV 4AWP GLY B 7 UNP P07900 EXPRESSION TAG SEQADV 4AWP SER B 8 UNP P07900 EXPRESSION TAG SEQRES 1 A 230 GLY SER ASP GLN PRO MET GLU GLU GLU GLU VAL GLU THR SEQRES 2 A 230 PHE ALA PHE GLN ALA GLU ILE ALA GLN LEU MET SER LEU SEQRES 3 A 230 ILE ILE ASN THR PHE TYR SER ASN LYS GLU ILE PHE LEU SEQRES 4 A 230 ARG GLU LEU ILE SER ASN SER SER ASP ALA LEU ASP LYS SEQRES 5 A 230 ILE ARG TYR GLU SER LEU THR ASP PRO SER LYS LEU ASP SEQRES 6 A 230 SER GLY LYS GLU LEU HIS ILE ASN LEU ILE PRO ASN LYS SEQRES 7 A 230 GLN ASP ARG THR LEU THR ILE VAL ASP THR GLY ILE GLY SEQRES 8 A 230 MET THR LYS ALA ASP LEU ILE ASN ASN LEU GLY THR ILE SEQRES 9 A 230 ALA LYS SER GLY THR LYS ALA PHE MET GLU ALA LEU GLN SEQRES 10 A 230 ALA GLY ALA ASP ILE SER MET ILE GLY GLN PHE GLY VAL SEQRES 11 A 230 GLY PHE TYR SER ALA TYR LEU VAL ALA GLU LYS VAL THR SEQRES 12 A 230 VAL ILE THR LYS HIS ASN ASP ASP GLU GLN TYR ALA TRP SEQRES 13 A 230 GLU SER SER ALA GLY GLY SER PHE THR VAL ARG THR ASP SEQRES 14 A 230 THR GLY GLU PRO MET GLY ARG GLY THR LYS VAL ILE LEU SEQRES 15 A 230 HIS LEU LYS GLU ASP GLN THR GLU TYR LEU GLU GLU ARG SEQRES 16 A 230 ARG ILE LYS GLU ILE VAL LYS LYS HIS SER GLN PHE ILE SEQRES 17 A 230 GLY TYR PRO ILE THR LEU PHE VAL GLU LYS GLU ARG ASP SEQRES 18 A 230 LYS GLU VAL SER ASP ASP GLU ALA GLU SEQRES 1 B 230 GLY SER ASP GLN PRO MET GLU GLU GLU GLU VAL GLU THR SEQRES 2 B 230 PHE ALA PHE GLN ALA GLU ILE ALA GLN LEU MET SER LEU SEQRES 3 B 230 ILE ILE ASN THR PHE TYR SER ASN LYS GLU ILE PHE LEU SEQRES 4 B 230 ARG GLU LEU ILE SER ASN SER SER ASP ALA LEU ASP LYS SEQRES 5 B 230 ILE ARG TYR GLU SER LEU THR ASP PRO SER LYS LEU ASP SEQRES 6 B 230 SER GLY LYS GLU LEU HIS ILE ASN LEU ILE PRO ASN LYS SEQRES 7 B 230 GLN ASP ARG THR LEU THR ILE VAL ASP THR GLY ILE GLY SEQRES 8 B 230 MET THR LYS ALA ASP LEU ILE ASN ASN LEU GLY THR ILE SEQRES 9 B 230 ALA LYS SER GLY THR LYS ALA PHE MET GLU ALA LEU GLN SEQRES 10 B 230 ALA GLY ALA ASP ILE SER MET ILE GLY GLN PHE GLY VAL SEQRES 11 B 230 GLY PHE TYR SER ALA TYR LEU VAL ALA GLU LYS VAL THR SEQRES 12 B 230 VAL ILE THR LYS HIS ASN ASP ASP GLU GLN TYR ALA TRP SEQRES 13 B 230 GLU SER SER ALA GLY GLY SER PHE THR VAL ARG THR ASP SEQRES 14 B 230 THR GLY GLU PRO MET GLY ARG GLY THR LYS VAL ILE LEU SEQRES 15 B 230 HIS LEU LYS GLU ASP GLN THR GLU TYR LEU GLU GLU ARG SEQRES 16 B 230 ARG ILE LYS GLU ILE VAL LYS LYS HIS SER GLN PHE ILE SEQRES 17 B 230 GLY TYR PRO ILE THR LEU PHE VAL GLU LYS GLU ARG ASP SEQRES 18 B 230 LYS GLU VAL SER ASP ASP GLU ALA GLU HET 99A A1224 38 HET 99A B1224 38 HETNAM 99A N-{(3-ENDO)-8-[5-(BENZYLCARBAMOYL)PYRIDIN-2-YL]-8- HETNAM 2 99A AZABICYCLO[3.2.1]OCT-3-YL}-2,5-DIMETHYLBENZENE-1,4- HETNAM 3 99A DICARBOXAMIDE FORMUL 3 99A 2(C30 H33 N5 O3) FORMUL 5 HOH *279(H2 O) HELIX 1 1 GLN A 23 THR A 36 1 14 HELIX 2 2 GLU A 42 ASP A 66 1 25 HELIX 3 3 PRO A 67 ASP A 71 5 5 HELIX 4 4 THR A 99 ASN A 106 1 8 HELIX 5 5 ALA A 111 GLN A 123 1 13 HELIX 6 6 ASP A 127 GLY A 135 5 9 HELIX 7 7 VAL A 136 LEU A 143 5 8 HELIX 8 8 GLU A 192 LEU A 198 5 7 HELIX 9 9 GLU A 199 SER A 211 1 13 HELIX 10 10 GLN B 23 THR B 36 1 14 HELIX 11 11 GLU B 42 ASP B 66 1 25 HELIX 12 12 PRO B 67 ASP B 71 5 5 HELIX 13 13 THR B 99 ASN B 106 1 8 HELIX 14 14 ALA B 111 GLN B 123 1 13 HELIX 15 15 ASP B 127 GLY B 135 5 9 HELIX 16 16 VAL B 136 LEU B 143 5 8 HELIX 17 17 GLU B 192 LEU B 198 5 7 HELIX 18 18 GLU B 199 SER B 211 1 13 SHEET 1 AA 8 GLU A 18 ALA A 21 0 SHEET 2 AA 8 SER A 169 THR A 174 -1 O PHE A 170 N PHE A 20 SHEET 3 AA 8 TYR A 160 SER A 164 -1 O ALA A 161 N ARG A 173 SHEET 4 AA 8 ALA A 145 LYS A 153 -1 O VAL A 148 N SER A 164 SHEET 5 AA 8 GLY A 183 LEU A 190 -1 O GLY A 183 N LYS A 153 SHEET 6 AA 8 THR A 88 ASP A 93 -1 O LEU A 89 N LEU A 188 SHEET 7 AA 8 ILE A 78 ASN A 83 -1 O ASN A 79 N VAL A 92 SHEET 8 AA 8 ILE A 218 LEU A 220 1 O THR A 219 N LEU A 80 SHEET 1 BA 8 GLU B 18 ALA B 21 0 SHEET 2 BA 8 SER B 169 THR B 174 -1 O PHE B 170 N PHE B 20 SHEET 3 BA 8 TYR B 160 SER B 164 -1 O ALA B 161 N ARG B 173 SHEET 4 BA 8 ALA B 145 LYS B 153 -1 O VAL B 148 N SER B 164 SHEET 5 BA 8 GLY B 183 LEU B 190 -1 O GLY B 183 N LYS B 153 SHEET 6 BA 8 THR B 88 ASP B 93 -1 O LEU B 89 N LEU B 188 SHEET 7 BA 8 ILE B 78 ASN B 83 -1 O ASN B 79 N VAL B 92 SHEET 8 BA 8 ILE B 218 LEU B 220 1 O THR B 219 N LEU B 80 SITE 1 AC1 23 ALA B 21 PHE B 22 GLN B 23 ASN B 51 SITE 2 AC1 23 SER B 52 ALA B 55 ASP B 93 MET B 98 SITE 3 AC1 23 LEU B 103 ILE B 104 ASN B 105 ASN B 106 SITE 4 AC1 23 LEU B 107 ILE B 110 PHE B 138 TYR B 139 SITE 5 AC1 23 TRP B 162 PHE B 170 THR B 184 HOH B2004 SITE 6 AC1 23 HOH B2019 HOH B2065 HOH B2067 SITE 1 AC2 22 ALA A 21 PHE A 22 GLN A 23 ASN A 51 SITE 2 AC2 22 SER A 52 ALA A 55 ASP A 93 MET A 98 SITE 3 AC2 22 LEU A 103 ILE A 104 ASN A 105 ASN A 106 SITE 4 AC2 22 LEU A 107 ILE A 110 PHE A 138 TYR A 139 SITE 5 AC2 22 TRP A 162 PHE A 170 HOH A2005 HOH A2036 SITE 6 AC2 22 HOH A2086 HOH A2089 CRYST1 44.307 56.904 57.457 70.48 87.20 69.02 P 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.022570 -0.008655 0.001951 0.00000 SCALE2 0.000000 0.018821 -0.006794 0.00000 SCALE3 0.000000 0.000000 0.018526 0.00000